Bleiweis et al. summarize in this single center retrospective study their experiences with the Berlin Heart EXCOR® VAD in 9 patients with single ventricle physiology.

The patients had a median weight of 4.0kg and a median length of 64 days of VAD support. 83% of patients bridged to transplant survived.

The authors come to the following conclusion:

“Pulsatile para-corporeal VAD as a bridge-to-transplant is a feasible option in supporting the failing stage-one single ventricle.”

“This small cohort has shown promise in utilizing a pulsatile paracorporeal ventricular assist device to bridge-to-transplant with positive outcomes.”

Read more about:

www.jtcvs.org/article/S0022-5223(20)32669-6/pdf

The use of EXCOR in patients with single ventricle physiology is not described in Berlin Heart's IFU of EXCOR sterile components. A separate labeling for EXCOR® Venous Cannula will be provided. This presentation describes data and investigator-initiated studies from centers who have decided to treat patients with single ventricle physiology using EXCOR.

The access to some or all shown products may be restricted by country-specific regulatory approvals. The use of EXCOR® VAD for adults, RVAD-support, Excor mobile and EXCOR® Active is not FDA-approved.